The ophthalmology portfolio consists of six new chemical entities (NCEs or molecules) that are under phase 3 trials and will be developed further by the Vitaris. The remaining oncology and dermatology business will be demerged into a new entity named Famy Pharma.
from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/G7zpxKq
https://ift.tt/x2yJaRu
from Latest Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/G7zpxKq
https://ift.tt/x2yJaRu
Post a Comment